Company Overview and News

 
FXBY / Foxby Corp. N-CSR

2018-03-08 sec.gov
Form 8-K
Upvote Downvote

 
Dividend and Income Fund Declares Quarterly Distribution

2018-03-01 accesswire
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / A quarterly distribution of $0.15 per share was declared today by Dividend and Income Fund (NYSE: DNI) (NASDAQ: XDNIX), payable March 29, 2018 to shareholders of record as of March 15, 2018.
Upvote Downvote

 
FXBY / Foxby Corp. ACCOUNTANT CONSENT LETTER

2018-02-26 sec.gov
PAGE 1 000 B000000 12/31/2017 000 C000000 0001068897 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6.1 000 J000000 A 001 A000000 FOXBY CORP. 001 B000000 811-09261 001 C000000 2127850900 002 A000000 11 HANOVER SQUARE 002 B000000 NEW YORK 002 C000000 NY 002 D010000 10005 003 000000 N 004 000000 N 005 000000 N 006 000000 N 007 A000000 N 007 B000000 0 007 C010100 1 007 C010200 2 007 C010300 3 007 C010400 4 007 C010500 5 007 C010600 6 007 C010700 7 007 C010800 8 0
Upvote Downvote

 
FXBY / Foxby Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
Foxby Corp. (OTC:FXBY) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 191,498 shares. Largest shareholders include Morgan Stanley, and Blue Bell Private Wealth Management, Llc.
Upvote Downvote

 
FXBY / Foxby Corp. / MORGAN STANLEY - MS INITIAL (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.0)* FOXBY CORP. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 351645106 ----------------------------------------------------- (CUSIP Number) December 29, 2017 ----------------------------------------------------- (Date Of Event which Re
Upvote Downvote

 
FXBY / Foxby Corp. / MORGAN STANLEY - MS INITIAL (Passive Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.0)* FOXBY CORP. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 351645106 ----------------------------------------------------- (CUSIP Number) December 29, 2017 ----------------------------------------------------- (Date Of Event which Re
Upvote Downvote

4
Buy Pershing Square At A 25% Discount To Net Asset Value

2018-01-12 seekingalpha
It is headed by an accomplished star manager who recently got his concentrated portfolio in trouble.
Upvote Downvote

 
Midas Funds 2017 Estimated Yearend Distribution

2017-12-18 accesswire
NEW YORK, NY / ACCESSWIRE / December 18, 2017 / The Midas Funds (NASDAQ: MIDSX) (NASDAQ: MISEX) announced today their 2017 preliminary estimated yearend dividends and capital gain distributions.
Upvote Downvote

 
Dividend and Income Fund Updates the Sources of Quarterly Distribution

2017-12-06 accesswire
NEW YORK, NY / ACCESSWIRE / December 6, 2017 / On December 1, 2017, Dividend and Income Fund (NYSE: DNI) (NASDAQ: XDNIX) declared a quarterly distribution of $0.15 per share, payable December 28, 2017 to shareholders of record as of December 15, 2017.
Upvote Downvote

 
Dividend and Income Fund Declares Quarterly Distribution

2017-12-01 accesswire
NEW YORK, NY / ACCESSWIRE / December 1, 2017 / A quarterly distribution of $0.15 per share was declared today by Dividend and Income Fund (NYSE: DNI) (NAV: XDNIX), payable December 28, 2017 to shareholders of record as of December 15, 2017.
Upvote Downvote

 
Foxby Corp. -

2017-11-17 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number:  811-09261 FOXBY CORP. (Exact name of registrant as specified in charter) 11 Hanover Square, 12th Floor New York, NY 10005 (Address of principal executive offices) (Zip Code) Russell L. Kamerman, Esq.
Upvote Downvote

 
Foxby 7G

2017-10-05 sec.gov
  ICI MUTUAL INSURANCE COMPANY, a Risk Retention Group 1401 H St. NW Washington, DC 20005 INVESTMENT COMPANY BLANKET BOND ICI MUTUAL INSURANCE COMPANY, a Risk Retention Group 1401 H St. NW Washington, DC 20005 DECLARATIONS NOTICE This policy is issued by your risk retention group.  Your risk retention group may not be subject to all of the insurance laws and regulations of your state.  State insurance insolvency guaranty funds are not available for your risk retention group.
Upvote Downvote

 
Foxby R

2017-10-04 sec.gov
fxby.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES       Investment Company Act file number:  811-09261     Foxby Corp. (Exact name of registrant as specified in charter)      11 Hanover Square, New York, NY  10005  (Address of principal executive offices)  (Zipcode)     John F. Ramirez, Esq.
Upvote Downvote

 
Foxby 9.906 CERT

2017-09-01 sec.gov
  Exhibit 99.906 CERT     SECTION 906 CERTIFICATION Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     Foxby Corp.           In connection with the report on Form N-CSRS (the "Report") of the above-named issuer for the period ended June 30, 2017 that is accompanied by this certification, the undersigned hereby certifies to the best of his knowledge that:   1.
Upvote Downvote

 
Foxby 9.CERT

2017-09-01 sec.gov
 Exhibit 99.CERT     CERTIFICATIONS   I, Thomas B. Winmill, certify that:   1. I have reviewed this report on Form N-CSRS of Foxby Corp.;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   3.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 351645106